I guess there are two elements to that. There's the maximum price allowed by the PMPRB, which is.... Depending on how the PMPRB evolves over the coming time, we don't know their role.
For most of the prices, whether it's a national pharmacare program, there's going to be a confidential listing agreement. There's a whole series of reasons for that, particularly for the newer products. I don't think there's going to be a big difference between what the pCPA does now and if everything were to be under a single plan. I don't think there would be a big difference.